News | November 13, 2008

Heart's Surplus Energy May Help Power Pacemakers, Defibrillators

November 14, 2008 - Surplus energy generated by the heart may one day help power pacemakers and defibrillators implanted in cardiac patients, according to research presented this week at the American Heart Association's Scientific Sessions 2008 in New Orleans.

In a trailblazing experiment, a microgenerator powered by heartbeats produced almost 17 percent of the electricity needed to run a pacemaker.

"This was a proof-of-concept study, and we proved the concept," said Paul Roberts, M.D., first author of the study and a consultant electrophysiologist at Southampton University Hospital in the U.K. "Harvesting surplus energy might be a major transition in implantable pacemakers and defibrillators because engineers will have more energy to work with."

In their study, researchers found at a heart rate of 80 beats per minute (bpm), the device yielded an average harvested energy of 4.3 microjoules per cardiac cycle. Increasing changes in the heart rate produced corresponding increases in energy. At 104 to 128 bpm, the harvested energy level increased 140 percent. Decreases occurred when the researchers slowed the heartbeat or lowered blood pressure. Researchers said implantation and surplus energy harvesting caused no significant injury to the lining of the heart's chambers.

"What this might mean is that in the next era of pacemakers, you'd get devices that lasted significantly longer and we could add more functions to help monitor the heart," Roberts said. "It's possible they could be efficient enough to allow complete and indefinite powering of pacemakers."

Since their introduction into clinical medicine, implantable pacemakers and defibrillators have saved lives and become more sophisticated. However, adding new monitoring capabilities to the devices has led designers to a critical point.

"The small devices now are really very good, but power consumption must increase if we want to take them to the next level," Dr. Roberts said. "Battery technology has plateaued and the only way we are going to increase power is to increase size."

This, in turn, would increase the units' weight, making them more uncomfortable and less cosmetically acceptable to patients because the devices are implanted under the skin.

The innovative generator, called the self-energizing implantable medical microsystem (SIMM), helps the heart produce more than enough energy with each beat to pump blood. The SIMM uses two compressible bladders and a microgenerator mounted on the lead of a pacemaker or defibrillator, the wire that connects the device to the heart.

The lead is attached to the end of the right ventricle, and the bladders relay the energy from the pressure of each heartbeat to the microgenerator, which transforms it into electricity for use by the battery.

A consortium of companies including InVivo Technology, Perpetuum and Zarlink Semiconductor developed and tested the SIMM microgenerator with U.K. government funds. Researchers used an in-vivo porcine model to evaluate the study. The researchers are now working to improve the materials used in the SIMM microgenerator.

"With different materials, we�re seeing even greater energy harvesting," Roberts said. "While at the moment we see about 20 percent harvesting, we're anticipating that will be significantly more in the next iteration of the device."

Dr. Roberts holds ownership interests in InVivo Technology and serves on its Scientific Advisory Board.

The United Kingdom Technology Strategy Board funded the SIMM project.

For more information: www.americanheart.org

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init